Companies: 10,795·Total market cap: $144.5T

TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

TCRXNASDAQHealthcare● Active

$1.01

+$0.01(+1.12%)

Market Cap$61379600

P/E Ratio—

52W High$2.57

52W Low$0.882

Avg Volume864K

Open$1.01

Beta1.03

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

TScan Therapeutics, Inc.（TCRX）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · TCRX · 截至 Jun 9, 2026

关键指标

EPS (TTM)—Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)—Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding—Shares outstanding history

Next EarningsTBAEarnings history

探索 TScan Therapeutics, Inc. 数据

分析师预测$8 · Buy

股息不分红

分析师评级与目标价

Buy8 位分析师

Strong Buy

0

Buy

7

Hold

1

Sell

0

Strong Sell

0

12-Month Price Target

$3.00Low

$1.00Current

$7.50Avg Target上涨空间 646.27%

$12.00High

合计: 8 · 买入占比: 87.5%

根据过去 3 个月内 8 位华尔街分析师，TCRX 共识评级为 Buy，12 个月平均目标价 $7.50 （较现价 $1.00 上涨空间 646.27%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

TScan Therapeutics, Inc.

$1.01+1.12%$61.4M #2

Adicet Bio, Inc.

$7.22+2.42%$67.5M #3

Acrivon Therapeutics, Inc. Common Stock

$1.41+2.84%$44.5M #4

Fortress Biotech, Inc.

$2.85+2.81%$94.7M #5

$12.06+6.55%$119.0M #6

Lite Strategy, Inc.

$0.75+3.52%$25.7M

关于 TScan Therapeutics, Inc.

CEOGavin MacBeath

IPO DateJul 16, 2021

Employees200

CountryUS

Websitetscan.com

TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The compan…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

TScan Therapeutics, Inc.（TCRX）是 Biotechnology 行业的 Healthcare 类公司，于 Jul 16, 2021 在 NASDAQ 上市。截至最近交易日，TCRX 股价为 $1.00，市值约为 $61.4M。过去12个月累计回报 —，年初至今回报 —。

常见问题

截至最近一个交易日，TScan Therapeutics, Inc.（TCRX）股价为 $1.00，在 NASDAQ 上市，52周区间为 $0.88 – $2.57。

TCRX 最新股价TCRX quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议